Bone Biologics Balance Sheet Health
Financial Health criteria checks 6/6
Bone Biologics has a total shareholder equity of $3.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.0M and $1.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.45m |
| Equity | US$3.79m |
| Total liabilities | US$1.18m |
| Total assets | US$4.98m |
Financial Position Analysis
Short Term Liabilities: BBLG's short term assets ($5.0M) exceed its short term liabilities ($1.2M).
Long Term Liabilities: BBLG has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: BBLG is debt free.
Reducing Debt: BBLG currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BBLG has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: BBLG is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.